- Home
- ISPC vs SILO Comparison
ISPC vs SILO Comparison
Compare ISPC & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISPC | SILO |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 5.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ISPC | SILO |
|---|---|---|
| Price | $0.37 | $0.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 541.1K | 117.5K |
| Earning Date | 11-17-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,352,744.00 | $72,102.00 |
| Revenue This Year | $35.93 | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.36 | $0.36 |
| 52 Week High | $3.38 | $3.37 |
Technical Indicators
Market Signals| Indicator | ISPC | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 31.06 | 36.86 |
| Support Level | $0.36 | $0.37 |
| Resistance Level | $0.44 | $0.43 |
| Average True Range (ATR) | 0.04 | 0.03 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 6.47 | 0.80 |
Price Performance
Historical ComparisonAbout ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.